Hematological Diseases Clinical Trial
Official title:
The Effect of Daily Ginger Drinking on Platelet's Function in the Saudi Population
This study aims to examine the effect of ginger beverage consumption on platelets activity
in apparently healthy Saudi adult volunteers.
As for the Saudi population, consumption of powdered ginger dissolved in hot water is a
common practice. Accordingly, in this study, it is tempting to speculate the effect of this
form of ginger consumption, given in separate time points per day, on platelet aggregation
profile by using platelet aggregation analogues. If positive results were obtained, the herb
could provide natural protection against the development of platelet aggregation
complications and could be a potential alternative to aspirin, used for improving blood
circulation and hematological pathophysiologies in diseased individuals.
Herbal medicine products are dietary supplements that people take to improve their health.
Many herbs have been used for a long time for claimed health benefits. They are sold as
tablets, capsules, powders, beverages, extracts and fresh or dried plants. Herbal medicines
have been associated with treatment of several physiological disorders of which
hematological, mainly clotting disorders. Those include garlic, onion, and ginger in
addition to pharmacological reagents such as aspirin, warfarin, heparin, and others. One of
the herbal medications affecting hematological profile is ginger which has gained focus
throughout studies conducted in previous years in the field of inhibiting platelet
aggregation, taking benefit from some undesirable side effects arising from the use of other
anti-platelet aggregation agents, especially aspirin.
Ginger (Zingiber officinale) is a well known spice and flavoring agent used in traditional
medicine in many countries. It is a source of valuable phytonutrients characterized by
having aromatic odor and pungent taste. The ginger rhizome contains 60% starch, 10%proteins,
10% fats, 5% fibers, 6% inorganic material, 10% residual moisture, 1-4% essential oils
including gingerol and zingiberene, in addition to pungent principles such as zingerone,
gingerol and shogaol. Shogaols are produced by heating gingerols. It has been speculated
that ginger can eliminate symptoms associated with a variety of illnesses since there are a
variety of chemical classes that these compounds belong to. Ginger has been used in the
management of headache, nervous diseases, nausea, and vomiting. It has also been used to
treat migraine headaches without side-effects. In addition, it is recommended in the
management of rheumatic disorders and muscular pain. Ginger also acts as a metabolic
enhancer where acetone extracts of ginger have stimulated bile secretion and excretion of
gallstones. Although ginger is considered a safe herbal medicine with only few and
insignificant adverse side effects, few undesirable effects like heartburn were noticed. In
quantities higher than 6 g ginger may act as a gastric irritant and inhalation of dust from
ginger may produce immunoglobulin E (IGE)-mediated allergy.
As for ginger toxicity, an acute overdose of ginger is usually in excess of about 2g of
ginger per kilogram of body mass depending on the ginger tolerance level and can result in a
state of central nervous system over-stimulation called "ginger gitters".
Experimental data reveals that ginger may be a dual inhibitor of eicosanoid synthesis,
inhibiting the synthesis of both prostaglandins and leukotrienes, which are inflammatory
mediators produced from arachidonic acid. With reference to the fact that normal platelet
functioning is linked to an interplay between those substances, ginger consumption appears
to be linked with reducing platelet aggregation.
Platelets have traditionally been linked with concepts of hemostasis and hemorrhagic
disorders. However, with increasing incidence of atherosclerosis and hematologic disorders,
the critical role played by platelets is more evident. Platelets are no longer viewed as
"scaffolding" for the events of the coagulation cascade but rather as important catalysts in
hemostasis, thrombosis, and fibrinolysis. Improved understanding of platelet physiology has
led to developments of pharmacologic adjuncts resulting in improved patency rates and
improved patient outcomes. Platelets are the smallest components in the blood stream, where
they exist as a-nucleate disc-shaped cells in their resting state and travel singly as
discoidal particles. In the presence of stimuli such as arachidonic acid, activated
platelets change shape into spiny spheres. They bind to fibrinogen, aggregate and release
the contents of their intracellular granules, including adenosine diphosphate (ADP) and
serotonin.
ADP and an arachidonic acid (AA) metabolite acting an endogenous platelet activator,
thromboxane A2 (TxA2), intensify the extent of platelet aggregation. ADP, arachidonic acid,
epinephrine, and collagen act as agonists for platelet aggregation and clumping. These
substances act in positive feedback loops, making platelet aggregation an autocatalytic
rather than equilibrium response. Under pathophysiological conditions, platelet activation
may result in peripheral, cardiovascular or cerebrovascular thrombosis with serious
consequences.
Aspirin has been the main anti-platelet therapeutic agent. Inhibition of platelet
aggregation by aspirin significantly reduces the incidence of first myocardial infarction,
recurrent infarction and vascular death among patients with cardiovascular disease. Aspirin
also reduces the risk of nonfatal stroke, nonfatal myocardial infarction and vascular death
in patients with possible risk factors. However, aspirin ingestion, is mainly associated
with gastric ulcers and gastrointestinal bleeding. Thus, the use of aspirin may be confined
to elderly patients whose benefits outweigh increased risks of gastrointestinal bleeding.
Gingerols and their derivatives, especially [8]-paradol, have been reported to be more
potent anti-platelet and cyclo-oxygenase-1 (COX-1) inhibitors than aspirin, when tested in
vitro by the Chrono Log whole blood platelet aggregometer. Note that COX-1 is the enzyme
responsible for the conversion of arachidonic acid into important biological mediators
including prostaglandins, prostacyclins, and thromboxanes. These authors proposed that the
carbonyl functional group at C3 found in paradol and in the diarylheptanoid series may
contribute to their potent anti-platelet activity and inhibition of COX-1. Inhibition of the
arachidonic acid (AA) metabolism cascade via the COX-1/thromboxane synthase system by these
phenolic compounds may underline the mechanism of their action. In 2001 Koo et al. compared
the ability of gingerols and related analogs to that of aspirin in inhibiting AA-induced
human platelet serotonin release in vitro. Using the same dose range, it has been found that
gingerols and related analogs were approximately two- to three-fold less potent than aspirin
against the platelet release reaction initiated by AA, and two- to four-fold less potent
than aspirin at inhibiting AA-induced platelet aggregation. Gingerols inhibited COX
activity, assessed by measuring prostaglandin D2, a product of AA metabolism by COX. These
results suggest that inhibition of COX activity by gingerols and related analogs may be the
underlying mechanism for their effect on AA-induced platelet activation. 6-gingerol inhibits
arachidonic acid-induced platelet aggregation and formation of thromboxane B2 and
prostaglandin D2. Gingerol, shogaol and other structurally related substances in ginger
inhibit prostaglandin and leukotriene biosynthesis.
Of the earlier studies conducted on ginger was that of Srivastava et al. in 1986 where they
found that 5g of fresh, raw ginger has inhibited thromboxane B2 formation.
Furthermore, a study done on 20 healthy male individuals that were given 50 g of butter and
5g of ginger a day for seven days showed that addition of ginger with a fatty meal inhibited
the platelet aggregation induced by adenosine diphosphate and epinephrine greatly. Ginger
has been reported to inhibit prostaglandin synthesis in vitro. Dietary fat content affects
platelet aggregation by modifying prostaglandin metabolism. Administration of ginger in a
fatty diet inhibits the transformation of arachidonic acid to thromboxane and decreases the
sensitivity of platelets to many aggregating agents. In 1994, Lumb et al., have shown in a
cross over study conducted on 8 subjects that 2g of powdered ginger (prepared as medication)
had no effect on bleeding time and whole blood platelet aggregation. Similarly, 15g and 40g
of fresh or cooked raw ginger did not induce platelet aggregation in a cross over study
conducted by Janssen et al. in 1996. Moreover, in 1997, Boardia et al. found that 4g of
ginger powder was ineffective, where as 10g reduced platelet aggregation. Tested via
addition of platelet aggregation agonists collagen, ADP, and epinephrine, platelet
aggregation was inhibited by 35.3%, 37.8%, and 35.9% respectively upon administration of 1g
dry ginger for a week. A combination of 1 g ginger with 10 mg nifedipine per day could be
valuable for cardiovascular and cerebrovascular complication due to platelet aggregation.
Therefore, studies conducted to study the effect of ginger on bleeding risk have found no
effect up to 15g raw ginger, 40g cooked ginger, or 4g dried ginger daily on platelet
aggregation whereas 10g of dried ginger decreased platelet aggregation.
Throughout previous years, several studies have been designed to study the effect of
different doses of different ginger forms (fresh, dry, extract, capsules) on platelet
aggregation profile. Although most of them have made the suspect true, still others possess
controversial results. In view of what literature has offered, it is most probable that
ginger anti-platelet effect could be dose dependent, form dependent, and probably population
or individual dependent as postulated by Helgason et al. in 1993 in their analysis of
aspirin and warfarin platelet aggregation effect. Previous studies might have also employed
old, non-reliable techniques in studying platelet aggregation profiles. As for the Saudi
population, consumption of powdered ginger dissolved in hot water is a common practice.
Accordingly, in this study, it is tempting to speculate the effect of this form of ginger
consumption, given in separate time points per day, on platelet aggregation profile by using
platelet aggregation analogues. If positive results were obtained, the herb could provide
natural protection against the development of platelet aggregation complications and could
be a potential alternative to aspirin, used for improving blood circulation and
hematological pathophysiologies in diseased individuals.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02241031 -
Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia
|
Phase 2/Phase 3 | |
Recruiting |
NCT02240992 -
MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment
|
Phase 2/Phase 3 | |
Completed |
NCT02483325 -
Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases
|
Phase 2 | |
Recruiting |
NCT05041933 -
Secure Outsourcing of Carfilzomib in the Treatment of Multiple Myeloma to the Hospital at Home Setting
|
||
Completed |
NCT00675038 -
Pilot Study of Non-Invasive Assessment of Hepatic And Myocardial Iron Through T2* Magnet Resonance Imaging (MRI) In Patients With Iron Overload
|
N/A | |
Active, not recruiting |
NCT03745287 -
A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05505760 -
Testing Content Delivery Models for MomConnect
|
N/A | |
Recruiting |
NCT01160952 -
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT00884364 -
Exercise During Chemotherapy for Patients With Hematological Malignancies
|
Phase 3 | |
Completed |
NCT00892502 -
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
|
N/A | |
Active, not recruiting |
NCT00838643 -
Invasive Aspergillosis After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
|
N/A | |
Recruiting |
NCT05329649 -
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
|
Phase 3 | |
Not yet recruiting |
NCT06281496 -
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02661035 -
Allo HSCT Using RIC for Hematological Diseases
|
Phase 2 | |
Enrolling by invitation |
NCT06277479 -
Late Effects and HRQoL in Survivors of Allo-HSCT - a Cross Sectional Study
|
||
Completed |
NCT00956358 -
Study on Systemic and Airway Biomarkers in Haemopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT01344681 -
Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases
|
Phase 2 | |
Recruiting |
NCT02083731 -
MSC for Treatment of CMV Infection
|
Phase 2 | |
Recruiting |
NCT02083718 -
Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function
|
Phase 2 | |
Recruiting |
NCT01763086 -
Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant
|
Phase 2 |